• Je něco špatně v tomto záznamu ?

Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality

T. Tarvasmäki, J. Lassus, M. Varpula, A. Sionis, R. Sund, L. Køber, J. Spinar, J. Parissis, M. Banaszewski, J. Silva Cardoso, V. Carubelli, S. Di Somma, A. Mebazaa, VP. Harjola, . ,

. 2016 ; 20 (1) : 208. [pub] 20160704

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18011134

BACKGROUND: Vasopressors and inotropes remain a cornerstone in stabilization of the severely impaired hemodynamics and cardiac output in cardiogenic shock (CS). The aim of this study was to analyze current real-life use of these medications, and their impact on outcome and on changes in cardiac and renal biomarkers over time in CS. METHODS: The multinational CardShock study prospectively enrolled 219 patients with CS. The use of vasopressors and inotropes was analyzed in relation to the primary outcome, i.e., 90-day mortality, with propensity score methods in 216 patients with follow-up data available. Changes in cardiac and renal biomarkers over time until 96 hours from baseline were analyzed with linear mixed modeling. RESULTS: Patients were 67 (SD 12) years old, 26 % were women, and 28 % had been resuscitated from cardiac arrest prior to inclusion. On average, systolic blood pressure was 78 (14) and mean arterial pressure 57 (11) mmHg at detection of shock. 90-day mortality was 41 %. Vasopressors and/or inotropes were administered to 94 % of patients and initiated principally within the first 24 hours. Noradrenaline and adrenaline were given to 75 % and 21 % of patients, and 30 % received several vasopressors. In multivariable logistic regression, only adrenaline (21 %) was independently associated with increased 90-day mortality (OR 5.2, 95 % CI 1.88, 14.7, p = 0.002). The result was independent of prior cardiac arrest (39 % of patients treated with adrenaline), and the association remained in propensity-score-adjusted analysis among vasopressor-treated patients (OR 3.0, 95 % CI 1.3, 7.2, p = 0.013); this was further confirmed by propensity-score-matched analysis. Adrenaline was also associated, independent of prior cardiac arrest, with marked worsening of cardiac and renal biomarkers during the first days. Dobutamine and levosimendan were the most commonly used inotropes (49 % and 24 %). There were no differences in mortality, whether noradrenaline was combined with dobutamine or levosimendan. CONCLUSION: Among vasopressors and inotropes, adrenaline was independently associated with 90-day mortality in CS. Moreover, adrenaline use was associated with marked worsening in cardiac and renal biomarkers. The combined use of noradrenaline with either dobutamine or levosimendan appeared prognostically similar.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011134
003      
CZ-PrNML
005      
20180417155635.0
007      
ta
008      
180404s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13054-016-1387-1 $2 doi
035    __
$a (PubMed)27374027
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Tarvasmäki, Tuukka $u Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, PO Box 340, 00029 HUS, Helsinki, Finland. tuukka.tarvasmaki@fimnet.fi.
245    10
$a Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality / $c T. Tarvasmäki, J. Lassus, M. Varpula, A. Sionis, R. Sund, L. Køber, J. Spinar, J. Parissis, M. Banaszewski, J. Silva Cardoso, V. Carubelli, S. Di Somma, A. Mebazaa, VP. Harjola, . ,
520    9_
$a BACKGROUND: Vasopressors and inotropes remain a cornerstone in stabilization of the severely impaired hemodynamics and cardiac output in cardiogenic shock (CS). The aim of this study was to analyze current real-life use of these medications, and their impact on outcome and on changes in cardiac and renal biomarkers over time in CS. METHODS: The multinational CardShock study prospectively enrolled 219 patients with CS. The use of vasopressors and inotropes was analyzed in relation to the primary outcome, i.e., 90-day mortality, with propensity score methods in 216 patients with follow-up data available. Changes in cardiac and renal biomarkers over time until 96 hours from baseline were analyzed with linear mixed modeling. RESULTS: Patients were 67 (SD 12) years old, 26 % were women, and 28 % had been resuscitated from cardiac arrest prior to inclusion. On average, systolic blood pressure was 78 (14) and mean arterial pressure 57 (11) mmHg at detection of shock. 90-day mortality was 41 %. Vasopressors and/or inotropes were administered to 94 % of patients and initiated principally within the first 24 hours. Noradrenaline and adrenaline were given to 75 % and 21 % of patients, and 30 % received several vasopressors. In multivariable logistic regression, only adrenaline (21 %) was independently associated with increased 90-day mortality (OR 5.2, 95 % CI 1.88, 14.7, p = 0.002). The result was independent of prior cardiac arrest (39 % of patients treated with adrenaline), and the association remained in propensity-score-adjusted analysis among vasopressor-treated patients (OR 3.0, 95 % CI 1.3, 7.2, p = 0.013); this was further confirmed by propensity-score-matched analysis. Adrenaline was also associated, independent of prior cardiac arrest, with marked worsening of cardiac and renal biomarkers during the first days. Dobutamine and levosimendan were the most commonly used inotropes (49 % and 24 %). There were no differences in mortality, whether noradrenaline was combined with dobutamine or levosimendan. CONCLUSION: Among vasopressors and inotropes, adrenaline was independently associated with 90-day mortality in CS. Moreover, adrenaline use was associated with marked worsening in cardiac and renal biomarkers. The combined use of noradrenaline with either dobutamine or levosimendan appeared prognostically similar.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a kardiotonika $x farmakokinetika $x terapeutické užití $7 D002316
650    _2
$a adrenalin $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D004837
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hemodynamika $x fyziologie $7 D006439
650    _2
$a mortalita v nemocnicích $7 D017052
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a tendenční skóre $7 D057216
650    _2
$a kardiogenní šok $x komplikace $x farmakoterapie $7 D012770
650    _2
$a přežití tkáně $x účinky léků $7 D014022
650    _2
$a vazokonstriktory $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D014662
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lassus, Johan $u Division of Cardiology, Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Varpula, Marjut $u Division of Cardiology, Heart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
700    1_
$a Sionis, Alessandro $u Intensive Cardiac Care Unit, Cardiology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
700    1_
$a Sund, Reijo $u Department of Social Research, Faculty of Social Sciences, Centre for Research Methods, University of Helsinki, Helsinki, Finland.
700    1_
$a Køber, Lars $u Rigshospitalet, Copenhagen University Hospital, Division of Heart Failure, Pulmonary Hypertension and Heart Transplantation, Copenhagen, Denmark.
700    1_
$a Spinar, Jindrich $u Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Parissis, John $u Heart Failure Clinic and Secondary Cardiology Department, Attikon University Hospital, Athens, Greece.
700    1_
$a Banaszewski, Marek $u Institute of Cardiology, Intensive Cardiac Therapy Clinic, Warsaw, Poland.
700    1_
$a Silva Cardoso, Jose $u Department of Cardiology, University of Porto, CINTESIS, Porto Medical School, São João Hospital Center, Porto, Portugal.
700    1_
$a Carubelli, Valentina $u Division of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University and Civil Hospital of Brescia, Brescia, Italy.
700    1_
$a Di Somma, Salvatore $u Department of Medical Sciences and Translational Medicine, University of Rome Sapienza, Emergency Medicine Sant'Andrea Hospital, Rome, Italy.
700    1_
$a Mebazaa, Alexandre $u INSERM U942, Hopital Lariboisiere, APHP and University Paris Diderot, Paris, France.
700    1_
$a Harjola, Veli-Pekka $u Emergency Medicine, University of Helsinki and Department of Emergency Medicine and Services, Helsinki University Hospital, PO Box 340, 00029 HUS, Helsinki, Finland.
700    1_
$a ,
773    0_
$w MED00006603 $t Critical care (London, England) $x 1466-609X $g Roč. 20, č. 1 (2016), s. 208
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27374027 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180417155734 $b ABA008
999    __
$a ok $b bmc $g 1288619 $s 1007946
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 20 $c 1 $d 208 $e 20160704 $i 1466-609X $m Critical care $n Crit Care $x MED00006603
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace